Protect Yourself While There’s Still Time …

The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.

4 simple steps to protect your privacy and money before it’s too late.

Jamey Mock Biography and Net Worth

CFO of Moderna

As Chief Financial Officer, Jamey Mock oversees financial, business development and business services functions at Moderna. Mr. Mock previously served as Senior Vice President and CFO of PerkinElmer, Inc., a life sciences, diagnostics and analytical solutions company, since May 2018. In his role at PerkinElmer, he had overall leadership responsibility for the strategy and operations of all Company finance functions. During that time, he was instrumental in transforming PerkinElmer into an organization with a strengthened financial profile for growth and profitability. Before that, Mr. Mock served for nearly 20 years in a wide range of financial oversight capacities within General Electric Company, both in the United States and overseas. Mr. Mock holds a Bachelor of Arts in economics from St. Lawrence University.

What is Jamey M. Mock's net worth?: The estimated net worth of Jamey M. Mock is at least $545,032.56 as of April 8th, 2024. Mr. Mock owns 5,048 shares of Moderna stock worth more than $545,033 as of April 27th. This net worth evaluation does not reflect any other assets that Mr. Mock may own. Learn More about Jamey M. Mock's net worth.
How do I contact Jamey M. Mock?: The corporate mailing address for Mr. Mock and other Moderna executives is 200 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. Moderna can also be reached via phone at (617) 714-6500 and via email at [email protected]. Learn More on Jamey M. Mock's contact information.
Has Jamey M. Mock been buying or selling shares of Moderna?: Within the last three months, Jamey M. Mock has sold $71,860.65 of Moderna stock. Most recently, James M. Mock sold 705 shares of the business's stock in a transaction on Monday, April 8th. The shares were sold at an average price of $101.93, for a transaction totalling $71,860.65. Following the completion of the sale, the chief financial officer now directly owns 5,048 shares of the company's stock, valued at $514,542.64. Learn More on Jamey M. Mock's trading history.
Who are Moderna's active insiders?: Moderna's insider roster includes Noubar Afeyan (Director), Juan Andres (Insider), Stephane Bancel (CEO), W. Cornwell (Director), Arpa Garay (Insider), Lori Henderson (General Counsel), Lori Henderson (General Counsel), Stephen Hoge (President), Lorence Kim (CFO), Shannon Klinger (Insider), David Meline (CFO), Jamey Mock (CFO), Elizabeth Nabel (Director), Paul Sagan (Director), and Tal Zaks (Insider). Learn More on Moderna's active insiders.
Are insiders buying or selling shares of Moderna?: During the last year, insiders at the sold shares 59 times. They sold a total of 845,770 shares worth more than $97,034,332.71. The most recent insider tranaction occured on April, 24th when Director Noubar Afeyan sold 15,000 shares worth more than $1,624,800.00. Insiders at Moderna own 15.7% of the company. Learn More about insider trades at Moderna.
Information on this page was last updated on 4/24/2024.

Jamey M. Mock Insider Trading History at Moderna

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/8/2024	Sell	705	$101.93	$71,860.65	5,048
2/29/2024	Sell	647	$94.57	$61,186.79	4,300
1/8/2024	Sell	772	$109.75	$84,727.00	3,632
10/6/2023	Sell	2,858	$102.50	$292,945.00	2,952

Jamey M. Mock Buying and Selling Activity at Moderna

Moderna Company Overview

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $107.97

$105.39

$108.19

50 Day Range

MA: $102.54

$86.99

$111.98

2 Week Range

Now: $107.97

$62.55

$142.79

Volume

2,245,667 shs

Average Volume

2,940,287 shs

Market Capitalization

$41.34 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.62